Luis Miguel Chong Chong serves as director of Disruptiva Works, S. A. de C. V., leading projects in the sustainable infrastructure and information and communication technologies sectors, With entrepreneurial experience extending to managing pharmaceutical products distribution and life sciences services, Luis Miguel Chong Chong has a longstanding interest in health care and human genomics.
As reported in Forbes, one major global health care trend centers on the development of applications-focused CRISPR-Cas9 tools. High precision RNA-driven gene editing tools that are able to cut the DNA sequence accurately were introduced for commercial applications only five years after being introduced, an accelerated timeframe within the gene editing world.
Able to accurately recognize specific animal, plant, and human DNA sequences, the technology employs endonuclease Cas9, a cutting enzyme, and provides scientists and clinicians with a precise, low-risk way of editing regions within the DNA sequence. With the inclusion of a preferred sequence of DNA within the edited region, desired traits in living beings are expressed. CRISPR’s commercial potential spans human genomics as well as animal and plant biotechnology and is expected to represent a $25 billion industry within the next 12 years.
This technology could be very useful in treating various genetic and chronic diseases, such as different types of cancers, cystic fibrosis (CF), sickle-cell disease, beta thalassemias, and blindness.
